Outsized Ventures

At Outsized Ventures we partner with founders pushing the boundaries of science and technology to solve the world’s greatest challenges. Some call it deep tech, others frontier tech, tough tech, hard tech or high tech - for us, it is simply the future.

Leiva, Rodrigo Mallo

General Partner

13 past transactions

Emitwise

Series A in 2022
Emitwise’s unique AI technology empowers companies to automatically measure, report, and reduce their carbon footprint across their operations and supply chain, future-proofing businesses for a zero-carbon world. The company is backed by top Silicon Valley investors and trusted by global businesses. Emitwise's mission is to empower businesses to respond to the climate emergency, accelerating the transition to a net-zero carbon world by equipping them with all the tools they need to drive emissions cuts across their operations and supply chain.

Molecule.one

Seed Round in 2021
Molecule One is an information technology based bio company. Their m1 platform spans the preclinical pipeline to maximize chemistry. Molecule One integrates artificial intelligence into a suite of tools to assist bench chemists, data scientists, and computational chemists.

Treos Bio

Series A in 2021
Treos Bio, Inc. is a computational immunology and immunotherapy company which has developed a proprietary technology to predict in silico likely responders to cancer immunotherapies and to design in silico next generation targeted immunotherapies for a large population of cancer patients.

Hoxton Farms

Seed Round in 2021
Based in London, UK, Hoxton Farms is growing real animal fat – without animals. The company combines cell biology and mathematical modelling to produce cultivated fat as an ingredient for the meat alternatives industry.

Magdrive

Seed Round in 2021
Magdrive is working on advanced spacecraft propulsion for satellites in Low Earth Orbit (LEO).

Living Optics

Seed Round in 2021
Living Optics is on a mission to make hyperspectral imaging widely accessible. Our pioneering technology captures data inaccessible to the human eye and conventional cameras and delivers information in an affordable and portable solution for a diverse range of industrial and consumer applications. The company, headquartered in the U.K., also maintains offices in Taiwan. In September 2022, the company raised $25 million for its Series A funding round.

Hoxton Farms

Seed Round in 2020
Based in London, UK, Hoxton Farms is growing real animal fat – without animals. The company combines cell biology and mathematical modelling to produce cultivated fat as an ingredient for the meat alternatives industry.

Kernal Biologics

Seed Round in 2020
Kernal creates mRNA therapies to cure diseases like COVID and cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. Kernal won three awards from Amgen and NASA. With roots at MIT, Harvard and Big Pharma, the team previously built a successful Biotech company and has deep expertise in mRNA space.

Biomage

Pre Seed Round in 2020
Biomage specializes in single-cell analysis transforming the life sciences. Our goal is to apply innovative computational methods to extract valuable insight from biological data, fueling cutting-edge research across biological disciplines. Our flagship product, the Biomage Single Cell Platform empowers researchers to take ownership of their single cell data analysis, generating deep biological insight in just a few clicks.

Fathom Computing

Seed Round in 2020
Fathom Radiant was created on the premise of applying first-principles thinking to create technology capable of enabling artificial general intelligence for the benefit of all. The company does not believe that the beneficial advancement of AI is unavoidable, and Faathom believes that as a company offering a critical layer in the AI technology stack, we can make a difference in how securely advanced AI systems are built and deployed.

Phenomic AI

Seed Round in 2020
Phenomic AI is a developer of a drug discovery platform designed to discovery and optimize therapeutics directly against phenotypic assays.The company's platform uses artificial intelligence to analyze phenotypes in complex disease models including high-content co-culture and 3D assays, enabling pharmaceutical companies to discover drugs in an easier way.

Mahana Therapeutics

Series A in 2020
Mahana Therapeutics develops digital treatments for people living with chronic health conditions that are designed to provide physical and psychological support that will be clinically proven to help patients feel better.

Temporall

Seed Round in 2020
Temporall provides an AI and analytics-based platform to give key performance insights to leadership teams. Temporall sits at the intersection of enterprise software and organisational science, bringing the very best of technology and human expertise to support our clients’ strategic needs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.